Aldeyra Therapeutics, Inc.
http://www.aldeyra.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aldeyra Therapeutics, Inc.
Aldeyra Claims Success In Final Phase III For First-In-Class Dry Eye Drug
The company plans to submit an NDA for reproxalap for dry eye disease based on the results and hailed the crossover trial design as unique in the therapeutic area.
Aldeyra Therapeutics Eyes First Line Market As Phase II Dry Eye Candidate Impresses
The firm’s lead asset, reproxalap, one-upped Novartis’s Xiidra in a mid-stage ophthalmology study, signalling its first-line promise in a market ridden with compliance issues.
Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.
Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m
Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aldexa Therapeutics, Inc.
- Helio Vision, Inc.
- Neuron Systems, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice